Managers / Q4 2019 · view latest →
Healthcare Value Capital, LLC
CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411
Summary
Healthcare Value Capital, LLC reported $34M in U.S.-listed holdings across 16 positions for Q4 2019.
Its largest position, Glaxosmithkline, represents 13.8% of the portfolio.
Compared with Q3 2019, the fund opened 0 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 80.6% · $27M
- Other · 19.4% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF TR | SOLD OUT | −50.0K | 0 | −$15M | $0 |
| PROSHARES TR II | SOLD OUT | −200.0K | 0 | −$4M | $0 |
| WBAWALGREENS BOOTS ALLIANCE INC | SOLD OUT | −50.0K | 0 | −$3M | $0 |
| NOVELION THERAPEUTICS INC | SOLD OUT | −1.40M | 0 | −$1M | $0 |
| GILDGILEAD SCIENCES INC | TRIMMED | −50.0K | 70.0K | −$3M | $5M |
| FOAMIX PHARMACEUTICALS LTD | ADDED | +100.0K | 400.0K | +$421,000 | $1M |
| ANTARES PHARMA INC | TRIMMED | −100.0K | 300.0K | +$72,000 | $1M |
| GREENLANE HLDGS INC | TRIMMED | −25.0K | 175.0K | −$108,000 | $570,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | GLAXOSMITHKLINE PLC | SPONSORED ADR | 13.83% | $5M | 100.0K |
| 2 | GILDGILEAD SCIENCES INChistory → | COM | 13.39% | $5M | 70.0K |
| 3 | ABBVABBVIE INChistory → | COM | 13.03% | $4M | 50.0K |
| 4 | CVSCVS HEALTH CORPhistory → | COM | 10.94% | $4M | 50.0K |
| 5 | TYME TECHNOLOGIES INC | COM | 8.96% | $3M | 2.17M |
| 6 | VKTXVIKING THERAPEUTICS INChistory → | COM | 5.90% | $2M | 250.0K |
| 7 | CAHCARDINAL HEALTH INChistory → | COM | 5.21% | $2M | 35.0K |
| 8 | CORAMERISOURCEBERGEN CORPhistory → | COM | 5.00% | $2M | 20.0K |
| 9 | CLOVIS ONCOLOGY INC | COM | 4.60% | $2M | 150.0K |
| 10 | ANTARES PHARMA INC | COM | 4.15% | $1M | 300.0K |
| 11 | MCKMCKESSON CORPhistory → | COM | 4.07% | $1M | 10.0K |
| 12 | FOAMIX PHARMACEUTICALS LTD | SHS | 3.43% | $1M | 350.0K |
| 13 | GREENLANE HLDGS INC | CL A | 1.68% | $570,000 | 175.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $51M | 25 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $50M | 23 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $45M | 22 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $30M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $30M | 18 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $39M | 19 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $59M | 26 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $34M | 16 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $55M | 22 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $53M | 19 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $26M | 10 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.